
Novo says Victoza bests MSD’s Januvia at lowering blood sugar
pharmafile | April 4, 2016 | News story | Research and Development | Novo Nordisk, Victoza
Novo Nordisk says its diabetes drug Victoza, in combination with metformin, outperformed MSD’s Januvia plus metformin in reducing HbA1c – a measure of high blood sugar.
The 26-week 407-patient LIRA-SWITCH trial assessed the effects of switching from Januvia (sitagliptin) plus metformin to Victoza (liraglutide) plus metformin.
The study showed that patients who switched to Victoza achieved a superior reduction in HbA1c compared to those who remained on Januvia: 1.14% versus 0.54%.
Additionally, adults who switched to Victoza experienced significantly greater body weight reductions compared to those who continued with their sitagliptin dose – at 3.31 kg versus 1.64 kg.
“The LIRA-SWITCH trial results provide valuable insight that adults uncontrolled on sitagliptin may achieve a superior HbA1c reduction with liraglutide 1.8 mg versus continuing on sitagliptin treatment,” says Dr Maximo Maislos, director of Western Negev Mobile Diabetes Clinic Program, and investigator of the LIRA-SWITCH trial. “These findings are valuable, as there is limited clinical evidence to guide treatment strategy when people with type 2 diabetes are uncontrolled on second-line therapy.”
More adults with type 2 diabetes treated with Victoza achieved their HbA1c targets, compared to those on sitagliptin, at 50.6% versus 26.9%. Victoza patients also demonstrated significantly greater reductions in fasting plasma glucose vs those treated with sitagliptin: 1.84 versus 0.73.
Joel Levy
Related Content

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …






